Start free trial
Markets US Stocks Health Technology Biotechnology

Altimmune, Inc
ALT NASDAQ

ALT
Altimmune, Inc NASDAQ
Trade now
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Trade now
Overview
Ideas Technicals Financials Index Component

ALT Stock Chart

Ideas

Videos only
Top authors: ALT
SwingPyro
SwingPyro
Follow Following Unfollow
Bullishcharts
Bullishcharts
Follow Following Unfollow
TradeWithTyler
TradeWithTyler
Follow Following Unfollow
Coronavirus Fear Index vs. VIX
INO+IBIO+ALT+TNXP+VXRT+NVAX+MRNA+APDN+APT+CODX
, 1D
INO+IBIO+ALT+TNXP+VXRT+NVAX+MRNA+APDN+APT+CODX: Coronavirus Fear Index vs. VIX

Smart money's keep buying up the covid related stocks. Could be a sign of upcoming volatility spike.

BUY
ALT
, 1D
Long
ALT: BUY

BUY

ALT MONTHLY BREAKOUT
ALT
, 1M
Long
ALT: ALT MONTHLY BREAKOUT

2X MONTHLY BREAKOUT

All set for $22?
ALT
, 1D
ALT: All set for $22?

Looks like it wants to go towards $22. Tight stop loss at 12.30.

ALT Price Targets with Expected Resistance and Supports
ALT
, 1D
Long
ALT: ALT Price Targets with Expected Resistance and Supports

Labeled are the price targets for the breakout uptrend. The ascending stop loss would be used when each level has been used as support.

Altimmune Announces FDA Clearance of AdCOVID™ IND Application!!!
ALT
, 60
Long
ALT: Altimmune Announces FDA Clearance of AdCOVID™ IND Application!!!

ALT: Altimmune, Inc. 2021-02-17 07:02:00 Altimmune Announces FDA Clearance of AdCOVID™ IND Application

$ALT
ALT
, 1D
Long
ALT: $ALT

Nice Cup, small handle

ALT huge opportunity if you play it right
ALT
, 1W
Long
ALT: ALT huge opportunity if you play it right

I want to see a rejection off the 0.618 fib and rests on the support for a huge run to the 1.618 around $43-60

MACD looking bullish, RSI going up.
ALT
, 1D
Long
ALT: MACD looking bullish, RSI going up.

MACD is widening green and RSI is heading up. 50 sma line is below the 200 sma line so i will wait for the golden cross to occur to open a position. Looking into the company this is a long hold for me. Not a financial advisor.

ALT Rounded Bottom
ALT
, 1D
ALT: ALT Rounded Bottom

Not Squat Scan 5 month accumulation with rounded bottom. Research catalysts. Could see ATH of 36.

Looks like a bottoming pattern
ALT
, 1D
Long
ALT: Looks like a bottoming pattern

I could imagine going in slowly

Altimmune BULLS are looking strong
ALT
, 1W
Long
ALT: Altimmune BULLS are looking strong

Made a call long ago from $8 to $30 and now its time for $13.64 to become $40! Weekly chart shows something big is coming in the next 3 weeks. Aside from the bullish news, the charts are bullish.

$ALT Altimmune Inc trying to Break resistance
ALT
, 15
Long
ALT: $ALT Altimmune Inc trying to Break resistance

Strong move on a very weak day Alert set for move above POC & 20MA @ $12.50 100ma first majro target

ALT - 30m chart
ALT
, 30
Long
ALT: ALT - 30m chart

BUY @ 11.10 SL closing below 11.00 T1 12.12 T2 12.80

$ALT Monday Prediction
ALT
, 60
Long
ALT: $ALT Monday Prediction

Looking like it may breakout, alert set at 11.88

could still pop, but i see no sign of a trend
ALT
, 1W Short
ALT: could still pop, but i see no sign of a trend

look for a dip entry at 7 if you want to long this, thats where i think you will get the best risk reward. its hard to chart this one and predict where it will go next though. id stay away! gl :)

ALT Reversal Incoming? +Trade Setup (>168% Profit Potential)
ALT
, 1D
Long
ALT: ALT Reversal Incoming? +Trade Setup (>168% Profit Potential)

Hello Fellow Traders, Today we are looking at Altimmune Inc (ALT) on the NASDAQ. We can see that on the last bullish wave, prices peaked at around $35. We can see since then a bullish continuation pattern, the falling wedge, has been printed. The price has broken out to the upside, retested the EMAs for support, and bounced back to consolidate just in the...

Buy ALT for 67% ROI
ALT
, 120
ALT: Buy ALT for 67% ROI

it's a perfect buy!

Show more ideas

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Biotechnology
Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

News